Europe’s EMA And Japan’s PMDA Forge Closer Links On Orphan Drugs
This article was originally published in The Pink Sheet Daily
The European Medicines Agency and Japan’s Pharmaceutical and Medical Devices Agency have agreed to share information on the regulatory environment for orphan drugs. The cooperation is aimed at reducing bureaucracy for small- to medium-sized enterprises and improving the authorization process.
You may also be interested in...
The "chatter" between reviewers and scientists at FDA and the European Medicines Agency appears to be increasing as the two bodies move toward renewing their confidential information sharing agreement
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.